What does Viking Therapeutics, Inc. do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase…
What is Viking Therapeutics, Inc.'s P/E and P/B ratio?
Viking Therapeutics, Inc. has a P/E ratio of -5.5 and a P/B ratio of 8.04.
What is Viking Therapeutics, Inc.'s debt-to-equity ratio?
Viking Therapeutics, Inc. has a debt-to-equity ratio of 0.01.
How much does Viking Therapeutics, Inc. owe compared with what it owns?
Viking Therapeutics, Inc. owes $0.22 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Viking Therapeutics, Inc.'s Positivity rank?
Viking Therapeutics, Inc. is ranked #5,520 of 6,774 companies globally and #3,013 of 4,000 in United States on PositoAI, with a Positivity Score of 17,083.
Does Viking Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Viking Therapeutics, Inc..
Where can I read the latest news about Viking Therapeutics, Inc.?
Recent headlines about Viking Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Viking Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Viking Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.